UPDATE: IntelliCell BioSciences Appoints Mr. Michael Hershman as Chairman of the Board of Directors
October 31 2013 - 10:09AM
Marketwired
UPDATE: IntelliCell BioSciences Appoints Mr. Michael Hershman as
Chairman of the Board of Directors
NEW YORK, NY--(Marketwired - Oct 31, 2013) - IntelliCell
BioSciences, Inc. (OTCQB: SVFC), a regenerative medicine company
utilizing adult autologous vascular cells (SVFCs) derived from the
blood vessels found in adipose tissue, announced today that it has
appointed Mr. Michael Hershman to serve as the Chairman of the
Board of Directors.
Mr. Hershman currently serves as President and CEO of the
Fairfax Group, a company he founded in 1983, that has been retained
by governments, corporations, law firms and international financial
institutions seeking strategic consultation. In December 2006,
Mr. Hershman was appointed as the independent compliance advisor to
the board of directors of Siemens AG, a company with more than
400,000 employees. He is a member of the board of directors of the
U.S. Chamber of Commerce Foundation, and advises the Chamber on
corporate compliance issues.He began his career in intelligence and
investigations in Europe as a special agent with U.S. Military
Intelligence, specializing in counter-terrorism. After leaving the
military, he moved to investigations of government misconduct and
financial fraud for the New York State Attorney General's Office
and the Office of the Mayor of New York City.
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Mr.
Michael Hershman is an internationally recognized expert on matters
relating to transparency, accountability, governance, financial
compliance. His proven track record of success and previous
board experience will provide invaluable council to IntelliCell as
we navigate the complex capital markets. Mr. Hershman's
knowledge in building world-renowned organizations as he has with
Fairfax Group will provide a strong competitive advantage as we
continue to establish ourselves as a leader within the regenerative
medical industry. His strong belief in the company's growth
potential and business value proposition is a testament to the
strength of our strategy."
Since 2008, Mr. Hershman has been named every consecutive year
to the Ethisphere Institute's list of the top 100 most influential
people in business ethics worldwide. Michael Hershman has given
hundreds of speeches throughout the world on issues related to
transparency and accountability and has provided commentary on ABC,
CBS, NBC, PBS, CNN, CNBC, MSNBC and the Fox News Channel as well as
countless national radio shows. For five years he was the co-host
of the Public Radio Law Show. He has been quoted and published in
the Wall Street Journal, the New York Times, the New York Post, the
Washington Post, USA Today, the Financial Times, the National Law
Journal and other print media.
About IntelliCell BioSciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell BioSciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. One of the revenue
streams IntelliCell is pursuing is placing its labs into Hospitals
and Ambulatory Surgical Centers. IntelliCell will also be seeking
to develop technology-licensing agreements with technology
developers, universities, and international business entities.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: Investors: Chris Camarra Alliance Advisors, LLC Email
Contact